Analog Devices (ADI) has been highlighted for its strong growth as a stock, with positive recommendations from Baird and Susquehanna. Its partnership with TSMC has boosted its capacity and resilience, despite weak Q2 forecasts due to excess supply. The US FDA has granted 510(k) clearance to its Sensinel product, indicating a positive future. However, Fisher Asset Management has cut its stake in ADI and there has been insider disposing of stock. ADI continues to receive institutional backing with 89% ownership. The company's Q1 2024 earnings and revenues beat expectations, but fell Y/Y. Meanwhile, in the medical wearables market, the use of analog devices is gaining traction. Analysts are cautiously optimistic as they await future earnings reports. Decoding ADI gives strategic SWOT insight, suggesting potential growth, but also risks of investment. Their automotive segment has recently teamed up with BMW, peeking interest in this field.
Analog Devices ADI News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sat, 11 May 2024 14:00:11 GMT -
